Kardioprotektive Wirkung von Prostaglandin E1 auf das reperfundierte ischämische Myokard im Tierversuch

  • Ch. Thiemermann
  • K. Schrör

Zusammenfassung

In den 60er Jahren konnte die Gruppe um Jennings [30] aufgrund ultrastruktureller Untersuchungen an reperfundierten ischämischen Herzen erstmals zeigen, daß in der Reperfusionsphase ein zusätzlicher, Reperfusions-assoziierter Myokardschaden auftritt. Dieser Befund, der in der Folgezeit auch von anderen Autoren bestätigt wurde [16], machte deutlich, daß die Wiederherstellung der normalen Blutversorgung des ischämischen Herzens nicht nur die während der Ischämie aufgetretene Myokarddestruktion demaskiert, sondern darüber hinaus zu zusätzlichen Myokardschäden führen kann. Während für die Pathogenese der ischämischen Myokardschädigung ein Mißverhältnis von Sauerstoffangebot und Bedarf von entscheidender Bedeutung ist, werden für den Reperfusionsschaden u. a. die Bildung von zytotoxischen Sauerstoffradikalen und eine damit verbundene Lipidperoxidation und ein erhöhter Ca++-Einstrom [11, 28] diskutiert. Als Quellen der Sauerstoffradikale werden vor allem aktivierte neutrophile Granulozyten angesehen [16]. In Übereinstimmung mit dieser Hypothese konnte z. B. gezeigt werden, daß durch eine experimentell erzeugte Granulozytopenie eine deutliche Verringerung der Infarktgröße bei temporärer Ischämie eintritt [22].

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Aiken JW, Gorman RR, Shebuski RJ (1979) Prevention of blockage of partially obstructed coronary arteries with prostacyclin correlates with inhibition of platelet aggregation. Prostaglandins 17: 483–494CrossRefPubMedGoogle Scholar
  2. 2.
    Baller D, Bretschneider HJ, Hellige G (1981) A critical look at currently used indirect indices of myocardial oxygen consumption. Basic Res Cardiol 76: 163–181CrossRefPubMedGoogle Scholar
  3. 3.
    Bednar M, Smith B, Pinto A, Mullane KM (1985) Nafazatrom-induced salvage of ischemic myocardium in anesthetized dogs is mediated through inhibition of neutrophil function. Circ Res 57: 131–141CrossRefPubMedGoogle Scholar
  4. 4.
    Bradley PP, Priebat DA, Christensen RD, Rothstein G (1982) Measurement of cutaneous inflammation: Estimation of neutrophil content with an enzyme marker. J Invest Dermatol 78: 206–209CrossRefPubMedGoogle Scholar
  5. 5.
    Darius H, Thomsen T, Schrör K (1987) Cardiovascular actions in vitro and cardioprotective effects in vivo of nileprost, a mixed type PGI2/PGE2 agonist. J Cardiovasc Pharmacol 10: 144–152CrossRefPubMedGoogle Scholar
  6. 6.
    DeChatelet LR, Long GD, Shirley PS, Bass DA, Thomas MJ, Henderson FE, Cohen MS (1982) Mechanism of the luminol-dependent chemiluminescence of human neutrophils. J Immunol 129: 1589–1592PubMedGoogle Scholar
  7. 7.
    Edhag O, Henriksson P, Wennmalm A (1983) Prostacyclin infusion in patients with acute myocardial infarction (preliminary report). N Eng J Med 308: 1032–1033Google Scholar
  8. 8.
    Fantone JC, Kinnes DA (1983) Prostaglandin E1 and Prostaglandin I2 modification of Superoxide production by human neutrophils. Biochem Biophys Res Commun 113: 506–513CrossRefPubMedGoogle Scholar
  9. 9.
    Goetzl EJ, Gorman RR (1977) Chemotactic and chemokinetic Stimulation of human eosinophil and neutrophil polymorphnuclear leukocyte Chemotaxis and random migration by 12-L-hydroxy-5,8,10,14-eicosatetraenoic acid. J Clin Invest 59: 179–187CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Golub M, Zia P, Matsumo M, Horten R (1975) Metabolism of Prostaglandin At and Et in man. J Clin Invest 56: 1404–1410CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Hearse DJ (1977) Reperfusion of the ischemic myocardium. J Mol Cell Cardiol 8: 605–616CrossRefGoogle Scholar
  12. 12.
    Hedqvist P, Wennmalm A (1971) Comparison of the effects of Prostaglandins E1β E2 and F2α on the sympathetically stimulated rabbit heart. Acta Physiol Scand 83: 156–162CrossRefPubMedGoogle Scholar
  13. 13.
    Jolly SR, Kane WJ, Bailie MB, Abrams GD, Lucchesi BR (1984) Canine myocardial reperfusion injury: its reduction by the combined administration of Superoxide dismutase and catalase. Circ Res 54: 277–285CrossRefPubMedGoogle Scholar
  14. 14.
    Judgutt BI, Hutchins GM, Bulkley BH, Becker LC (1981) Dissimilar effects of prostacyclin, Prostaglandin E1 and Prostaglandin E2 on myocardial infarct size after coronary occlusion in conscious dogs. Circ Res 49: 685–700CrossRefGoogle Scholar
  15. 15.
    Kato T, Wokalek H, Schopf E, Eggert H, Rietschel ET, Fischer H (1981) Measurement of chemiluminescence in freshly drawn human blood. I. Role of granulocytes, platelets and plasma factors in zymosan-induced chemiluminescence. Klin Wschr 59: 203–211CrossRefPubMedGoogle Scholar
  16. 16.
    Lucchesi BR, Mullane KM (1986) Leucocytes and ischemia-induced myocardial injury. Ann Rev Pharmacol Toxicol 26: 201–224CrossRefGoogle Scholar
  17. 17.
    McCluskey ER, Murphree S, Saffitz JE, Morrison AR, Needleman P (1985) Temporal changes in 12-HETE formation in two models of canine myocardial infarction. Prostaglandins 29 (3): 387–403CrossRefPubMedGoogle Scholar
  18. 18.
    Mullane KM, McGiff JC (1985) Platelet depletion and infarct size in an occlusion-reperfusion model of myocardial ischemia in anaesthetized dogs. J Cardiovasc Pharmacol 7: 773–738CrossRefGoogle Scholar
  19. 19.
    Mullane KM, Read N, Salmon JA, Moncada S (1984) Role of leukocytes in acute myocardial infarction in anaesthetized dogs: Relationship to myocardial salvage by antiinflammatory drugs. J Pharmacol Exp Ther 228: 510–522PubMedGoogle Scholar
  20. 20.
    Ogletree ML, Lefer AM, Smith JB, Nicolaou KC (1979) Studies on the protective effect of prostacyclin in acute myocardial ischemia. Eur J Pharmacol 56: 95–103CrossRefPubMedGoogle Scholar
  21. 21.
    Prinzen FW, Van der Vusse GJ, Arts T, Roemen THM, Coumans WA, Renemann RS (1984) Accumulation of nonesterified fatty acids in ischemic canine myocardium. Am J Physiol 247: H264–H272PubMedGoogle Scholar
  22. 22.
    Romson JL, Hook BG, Kunkel SL, Abrams GD, Schork MA, Lucchesi BR (1983) Reduction of the extent of ischemic injury by neutrophil depletion in the dog. Circulation 67: 1016–1023CrossRefPubMedGoogle Scholar
  23. 23.
    Schrör K (1987) Eicosanoids and myocardial ischemia. Basic Res Cardiol 82, Suppl 1: 235–243Google Scholar
  24. 24.
    Schrör K, Ohlendorf R, Darius H (1981) Beneficial effects of a new carbacyclin derivative, ZK 36374, in acute myocardial ischemia. J Pharmacol Exp Ther 219: 243–249PubMedGoogle Scholar
  25. 25.
    Schrör K, Hecker G (1987) Potent inhibition of Superoxide anion generation by PGE! and the PGEj-analog OP-1206 in human PNN’s-unrelated to it’s anti-platelet, PGI2-like activity. Vasa 17, Suppl: 11–16Google Scholar
  26. 26.
    Schrör K, Thiemermann C, Ney P: Cardioprotective actions of PGEt in experimental myocardial ischemia-involvement of an antineutrophil component (submitted for publication)Google Scholar
  27. 27.
    Sharma B, Wyeth RP, Gimenez HJ, Franciosa JA (1986) Intracoronary Prostaglandin E! plus Streptokinase in acute myocardial infarction. Am J Cardiol 58: 1161–1166CrossRefPubMedGoogle Scholar
  28. 28.
    Shen AC, Jennings RB (1972) Myocardial calcium and magnesium in acute ischemic injury. Am J Pathol 67: 417–40PubMedPubMedCentralGoogle Scholar
  29. 29.
    Simpson PJ, Mitsos SE, Ventura A, Gallagher AP, Fantone JC, Abrams GD, Schork MA, Lucchesi BR (1987) Prostacyclin protects ischemic reperfused myocardium in the dog by inhibition of neutrophil activation. Am Heart J 113: 129–137CrossRefPubMedGoogle Scholar
  30. 30.
    Sommers HM, Jennings RB (1964) Experimental acute myocardial infarction induced by temporary or permanent occlusion of a coronary artery. Lab Invest 13: 1491–1503PubMedGoogle Scholar
  31. 31.
    Szczeklik A, Gryglewski RJ (1985) Prostaglandins in Therapy of cardiovascular disease. Adv Prostaglandin Thromboxane Leukotriene Res 13: 345–354Google Scholar
  32. 32.
    Thiemermann C (1987) Zur Bedeutung von Prostacyclin und Thromboxan für den Reperfusionsschaden des ischämischen Myokards. Inauguraldissertation, KölnGoogle Scholar
  33. 33.
    Thiemermann C, Steinhagen-Thiessen E, Schrör K (1984) Inhibition of oxygen-centered free radical formation by the stable prostacyclin-mimetic Iloprost (ZK 36 374) in acute myocardial ischemia. J Cardiovasc Pharmacol 6: 365–366CrossRefPubMedGoogle Scholar
  34. 34.
    Thiemermann C, Löbel P, Schrör K (1985) Usefulness of defibrotide in protecting ischemic myocardium from reperfusion damage. Am J Cardiol 56: 978–982CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1988

Authors and Affiliations

  • Ch. Thiemermann
  • K. Schrör

There are no affiliations available

Personalised recommendations